Heart:≤55岁急性冠脉综合征患者前驱症状有何性别差异?

2017-06-13 安雅晶; 环球医学

2017年6月,发表在《Heart》的一项由加拿大科学家进行的研究考察了55岁或以下的急性冠脉综合征(ACS)患者前驱症状的性别差异。

2017年6月,发表在《Heart》的一项由加拿大科学家进行的研究考察了55岁或以下的急性冠脉综合征(ACS)患者前驱症状的性别差异。

背景:研究表明,年轻女性不能识别早期ACS症状的风险最高。

目的:旨在检测ACS急性表现前数天和数周发生的前驱症状的性别差异。研究人员也检测了年轻患者中,追求健康的行为和院前管理

方法:1145名≤55岁的住院ACS患者的(368名女性)前瞻性横断面分析,这些患者来自于心血管疾病的性别和性别决定因素:从实验室到超越性急性冠状动脉综合征的队列研究(2009年1月~2013年4月)。使用McSweeney急性和前驱心肌梗死症状调查问卷确定前驱症状。通过调查问卷确定追求健康的行为和院前护理。

结果:中位年龄49岁。前驱症状发生率较高,报告症状的女性比男性多(85% vs 72%;P<0.0001)。性别间症状相似,包括异常疲劳、睡眠障碍、焦虑和手臂无力/不适。两性别的胸痛都不常见(24%)。女性更可能寻求治疗(49% vs 42%;P=0.04)。寻求治疗的患者中,女性比男性更可能因ACS使用救护车(52% vs 39%)。心血管风险降低治疗的使用在所有患者中都较低(≤40%),少于一半的患者认为他们的医生怀疑心脏起因。

结论:ACS前,女性比男性更可能出现前驱症状,并寻求就医。院前护理在性别间一般是相似的,但是处于风险的年轻人中,风险降低的治疗不足。

原始出处:

Khan NA, Daskalopoulou SS, et al. Sex differences in prodromal symptoms in acute coronary syndrome in patients aged 55 years or younger. Heart. 2017 Jun;103(11):863-869. doi: 10.1136/heartjnl-2016-309945. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2054257, encodeId=1a37205425e6c, content=<a href='/topic/show?id=4fda3269ed6' target=_blank style='color:#2F92EE;'>#前驱症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32697, encryptionId=4fda3269ed6, topicName=前驱症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Tue Sep 12 23:09:00 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211372, encodeId=85b22113e2af, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。给点赞啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Jun 16 07:05:08 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356333, encodeId=648a13563335d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430848, encodeId=2ab8143084888, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562566, encodeId=b443156256606, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2054257, encodeId=1a37205425e6c, content=<a href='/topic/show?id=4fda3269ed6' target=_blank style='color:#2F92EE;'>#前驱症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32697, encryptionId=4fda3269ed6, topicName=前驱症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Tue Sep 12 23:09:00 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211372, encodeId=85b22113e2af, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。给点赞啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Jun 16 07:05:08 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356333, encodeId=648a13563335d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430848, encodeId=2ab8143084888, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562566, encodeId=b443156256606, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2017-06-16 ylzr123

    认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。给点赞啦

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2054257, encodeId=1a37205425e6c, content=<a href='/topic/show?id=4fda3269ed6' target=_blank style='color:#2F92EE;'>#前驱症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32697, encryptionId=4fda3269ed6, topicName=前驱症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Tue Sep 12 23:09:00 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211372, encodeId=85b22113e2af, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。给点赞啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Jun 16 07:05:08 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356333, encodeId=648a13563335d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430848, encodeId=2ab8143084888, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562566, encodeId=b443156256606, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2017-06-15 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=2054257, encodeId=1a37205425e6c, content=<a href='/topic/show?id=4fda3269ed6' target=_blank style='color:#2F92EE;'>#前驱症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32697, encryptionId=4fda3269ed6, topicName=前驱症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Tue Sep 12 23:09:00 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211372, encodeId=85b22113e2af, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。给点赞啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Jun 16 07:05:08 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356333, encodeId=648a13563335d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430848, encodeId=2ab8143084888, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562566, encodeId=b443156256606, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2054257, encodeId=1a37205425e6c, content=<a href='/topic/show?id=4fda3269ed6' target=_blank style='color:#2F92EE;'>#前驱症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32697, encryptionId=4fda3269ed6, topicName=前驱症状)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Tue Sep 12 23:09:00 CST 2017, time=2017-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=211372, encodeId=85b22113e2af, content=认真学习,把间接经验应用到临床实践中去,然后再总结出新思路。给点赞啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Fri Jun 16 07:05:08 CST 2017, time=2017-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356333, encodeId=648a13563335d, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430848, encodeId=2ab8143084888, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562566, encodeId=b443156256606, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Thu Jun 15 08:09:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2017-06-15 slcumt

相关资讯

JACC:经桡动脉或股动脉侵入性治疗急性冠脉综合征后的肾损伤

在接受侵入性治疗的ACS患者中,与FA相比RA与AKI的风险降低相关。

Circulation:吡格列酮能否降低缺血性卒中或短暂缺血发作后的ACS风险?

胰岛素抵抗在动脉粥样硬化患者中发病率较高,并与心梗(MI)和卒中风险的增加相关。IRIS试验证实,吡格列酮会降低不合并糖尿病的胰岛素抵抗患者近期缺血性卒中或短暂缺血发作后的致命性或非致命性卒中和MI的复合风险。该人群中,心脏事件的类型和严重程度以及吡格列酮对这些事件的影响尚未进行过描述。2017年5月,《Circulation.》的一项研究对此进行分析。

Lancet:急性冠脉综合征临床显著出血:P2Y12抑制剂+利伐沙班vs阿司匹林

2017年5月,发表在《Lancet》的一项研究调查了急性冠脉综合征患者使用P2Y12抑制剂+低剂量利伐沙班vs阿司匹林的临床显着出血风险。背景:阿司匹林联合P2Y12抑制剂的双重抗血小板疗法(DAPT)是急性冠脉综合征后标准的抗血栓形成疗法。Xa因子抑制剂利伐沙班与DAPT联合使用时,可以降低死亡率和缺血性事件,但增加了出血风险。尚无低剂量利伐沙班(代替阿司匹林)和P2Y12抑制剂联合的双重通路

Eur Heart J: 急性冠脉综合征后双重抗血小板治疗中,普拉格雷+替卡格雷vs氯吡格雷

近年来急性冠脉综合征(ACS)的发病率呈上升趋势。ACS发生的关键是血小板活化聚集,我国目前治疗ACS使用最广泛的是低剂量阿司匹林联合P2Y12受体拮抗剂的方案。氯吡格雷是目前我国应用最广的P2Y12受体拮抗剂,但它是一种前体药物,存在起效 慢、药物抵抗、对P2Y12受体不逆性抑制、停药后血小板功能恢复时间长等缺点。既往的研究证明在缺血性ACS后使用新型P2Y12受体阻滞剂(普拉格雷和替卡格

NEJM:Evacetrapib不能有效降低患者心血管事件风险

Evacetrapib可显著改善患者脂蛋白生物指标但不能有效降低患者心血管事件风险

Eur Heart J:ACS后使用抗血小板治疗MI和出血的利弊并不难测

双联抗血小板用于急性冠脉综合征(ACS)患者是一把双刃剑,如何权衡预防缺血事件的获益和出血事件的危害,一直是临床医生面临的难题。2017年3月,发表在《Eur Heart J》的一项研究显示,ACS后使用抗血小板治疗的患者中,MI和出血均显着影响死亡率且具有相似的时间依赖性。目的:双联抗血小板治疗能减少急性冠脉综合征(ACS)的非致命性缺血事件,但会相同程度的增加出血。研究者试图考察在延长的随访期